Total Payments
$593,945
2024 Payments
$258,416
Companies
25
Transactions
578
Medicare Patients
550
Medicare Billing
$123,226
Payment Breakdown by Category
Other$328,423 (55.3%)
Consulting$191,765 (32.3%)
Travel$54,804 (9.2%)
Food & Beverage$13,353 (2.2%)
Research$5,600 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $324,523 | 86 | 54.6% |
| Consulting Fee | $191,765 | 83 | 32.3% |
| Travel and Lodging | $54,804 | 178 | 9.2% |
| Food and Beverage | $13,353 | 204 | 2.2% |
| Unspecified | $5,600 | 24 | 0.9% |
| Honoraria | $3,900 | 3 | 0.7% |
Payments by Type
General
$588,345
554 transactions
Research
$5,600
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BeiGene USA, Inc. | $157,786 | 115 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $154,787 | 143 | $0 (2024) |
| ABBVIE INC. | $111,063 | 129 | $0 (2024) |
| Lilly USA, LLC | $70,375 | 39 | $0 (2024) |
| Genentech USA, Inc. | $42,990 | 48 | $0 (2024) |
| Eli Lilly and Company | $25,062 | 33 | $0 (2024) |
| Octapharma USA, Inc. | $9,766 | 31 | $0 (2023) |
| Genentech, Inc. | $7,367 | 5 | $0 (2023) |
| AstraZeneca UK Limited | $4,110 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,960 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $258,416 | 215 | BeiGene USA, Inc. ($76,491) |
| 2023 | $232,396 | 237 | AstraZeneca Pharmaceuticals LP ($73,243) |
| 2022 | $44,276 | 45 | AstraZeneca Pharmaceuticals LP ($15,762) |
| 2021 | $25,357 | 19 | Eli Lilly and Company ($9,450) |
| 2020 | $12,685 | 10 | Novartis Pharmaceuticals Corporation ($3,960) |
| 2019 | $12,862 | 36 | AbbVie, Inc. ($7,149) |
| 2018 | $5,256 | 9 | AbbVie, Inc. ($5,256) |
| 2017 | $2,697 | 7 | Pharmacyclics LLC, An AbbVie Company ($2,697) |
All Payment Transactions
578 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $3,625.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,870.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $76.00 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $21.44 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $6.79 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $136.68 | General |
| Category: Oncology | ||||||
| 12/08/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $49.12 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Eli Lilly and Company | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $300.01 | General |
| Category: Oncology | ||||||
| 12/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | EPKINLY (Drug) | Consulting Fee | Cash or cash equivalent | $3,625.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $55.71 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Genentech USA, Inc. | Columvi (Biological), Venclexta | Food and Beverage | In-kind items and services | $50.46 | General |
| Category: BioOncology | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 11/26/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $363.24 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $288.22 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NGAM-12 | Octapharma USA, Inc. | $4,317 | 21 |
| NGAM?12 | Octapharma USA, Inc. | $1,283 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 137 | 441 | $225,194 | $47,810 |
| 2022 | 5 | 139 | 294 | $101,227 | $26,102 |
| 2021 | 4 | 117 | 251 | $81,591 | $22,019 |
| 2020 | 6 | 157 | 343 | $106,690 | $27,295 |
Total Patients
550
Total Services
1,329
Medicare Billing
$123,226
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 336 | $152,544 | $34,279 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 34 | $27,166 | $5,369 | 19.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 35 | $30,870 | $5,181 | 16.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 15 | 16 | $7,568 | $1,583 | 20.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 18 | 20 | $7,046 | $1,398 | 19.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 165 | $49,830 | $12,933 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 38 | 54 | $21,648 | $5,543 | 25.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 26 | $15,037 | $3,970 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 34 | $10,062 | $2,442 | 24.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 15 | 15 | $4,650 | $1,215 | 26.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 26 | 131 | $39,807 | $10,606 | 26.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 50 | 73 | $27,630 | $7,887 | 28.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 30 | 36 | $10,709 | $2,612 | 24.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 11 | $3,445 | $914.54 | 26.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 34 | 160 | $49,324 | $13,340 | 27.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 40 | 76 | $26,476 | $6,045 | 22.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 37 | 55 | $14,332 | $3,164 | 22.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 16 | $9,496 | $2,588 | 27.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 14 | 16 | $5,066 | $1,367 | 27.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 17 | 20 | $1,996 | $791.55 | 39.7% |
About Dr. Catherine Coombs, M.D
Dr. Catherine Coombs, M.D is a Hematology & Oncology healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2010. The National Provider Identifier (NPI) number assigned to this provider is 1417273517.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Catherine Coombs, M.D has received a total of $593,945 in payments from pharmaceutical and medical device companies, with $258,416 received in 2024. These payments were reported across 578 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($324,523).
As a Medicare-enrolled provider, Coombs has provided services to 550 Medicare beneficiaries, totaling 1,329 services with total Medicare billing of $123,226. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Orange, CA
- Active Since 04/14/2010
- Last Updated 11/04/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1417273517
Products in Payments
- BRUKINSA (Drug) $155,036
- CALQUENCE (Drug) $144,824
- VENCLEXTA (Drug) $71,948
- JAYPIRCA (Drug) $43,838
- Venclexta (Biological) $34,986
- Venclexta (Drug) $11,031
- VENCLEXTA (Biological) $7,564
- PANZYGA (Biological) $5,600
- EPKINLY (Drug) $4,604
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $4,166
- IMBRUVICA (Drug) $4,109
- Imbruvica (Drug) $2,697
- Lunsumio (Biological) $1,560
- NO PRODUCT DISCUSSED (Drug) $573.25
- Columvi (Biological) $293.48
- Lumoxiti (Drug) $250.00
- clonoSEQ (Device) $187.26
- Gazyva (Biological) $163.93
- Ultomiris (Drug) $150.00
- VYXEOS (Drug) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Orange
Dr. Arash Rezazadeh Kalebasty, M.d, M.D
Hematology & Oncology — Payments: $842,766
Hematology & Oncology $842,766
Sai-Hong I Ou, Md, MD
Hematology & Oncology — Payments: $489,003
Hematology & Oncology $489,003
Dr. Misako Nagasaka, Md, MD
Hematology & Oncology — Payments: $411,234
Hematology & Oncology $411,234
John P Fruehauf, Md, MD
Hematology & Oncology — Payments: $185,304
Hematology & Oncology $185,304
Timothy Byun, Md, MD
Hematology & Oncology — Payments: $137,826
Hematology & Oncology $137,826
Sam Huang, M.d, M.D
Hematology & Oncology — Payments: $104,843
Hematology & Oncology $104,843